Harvard Medical School

Dr. Louise Aronson Announced as 2023 Distinguished Ambassador in Aging by Aging Life Care Association®

Retrieved on: 
Monday, March 20, 2023
MFA, University, Teaching, ALCA, American Geriatrics Society, Research, DAA, Harvard Medical School, Philosophy, Pulitzer Prize, MD, Patient, Gold, Division, Health, Conference, Disease, Nursing, Humanism, Medicine, Ageing, Geriatrics

TUCSON, Ariz., March 20, 2023 /PRNewswire-PRWeb/ -- The Aging Life Care Association® (ALCA), will honor Louise Aronson, MD, MFA, as the 2023 Distinguished Ambassador in Aging Award recipient. Aronson is a leading geriatrician, writer, educator, and professor in the Division of Geriatrics at the University of California, San Francisco. Her book Elderhood was a 2020 Pulitzer Prize finalist.

Key Points: 
  • The Aging Life Care Association® (ALCA), will honor Louise Aronson, MD, MFA, as the 2023 Distinguished Ambassador in Aging Award recipient.
  • TUCSON, Ariz., March 20, 2023 /PRNewswire-PRWeb/ -- The Aging Life Care Association® (ALCA), will honor Louise Aronson, MD, MFA, as the 2023 Distinguished Ambassador in Aging Award recipient.
  • Aging Life Care Professionals focus on guiding individuals and families to actions and decisions that ensure quality care and an optimal life.
  • The conference (April 19-21, 2023) is a gathering of approximately 400 Aging Life Care Managers focused on excellence in the aging field.

Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board

Retrieved on: 
Monday, March 20, 2023
Infectious Diseases, Neurology, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, SAB, Tic disorder, Duchenne muscular dystrophy, MBA, CRD, Duchenne, NIH Intramural Research Program, Harvard Medical School, Biochemistry, Molecular genetics, SCA3, Cardiology, ASO, Rare, ADSSL1, Vaccine, Management, Pediatrics

As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.

Key Points: 
  • As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.
  • The members of the newly appointed SAB bring a wealth of expertise and experience in the areas of treatment and therapeutic development for neuromuscular diseases.
  • "Their insights and guidance will be critical as we continue to advance our programs and work towards our goal of providing life-saving treatments to individuals with rare diseases."
  • Collectively, these programs offer pragmatic hope of treatment to more than 200,000 Americans living with rare and ultra-rare diseases.

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

DermaSensor Unveils Study Results Demonstrating Ability to Detect Skin Cancer With Device Granted FDA Breakthrough Designation

Retrieved on: 
Friday, March 17, 2023
Other Health, Other Science, Pharmaceutical, Research, Oncology, Medical Devices, Hospitals, Science, Practice Management, Clinical Trials, Managed Care, Medical Supplies, General Health, FDA, Biotechnology, Alternative Medicine, Surgery, Health, DERM, University, Yale School of Medicine, Mayo Clinic, PCP, Skin, Florida State University, Trinity University, Medical college, University of Connecticut, Skin cancer, Cancer, Medical College of Georgia, Multimedia, Clarence, PPV, Harvard Medical School, Therapy, NPV, Patient, AAD, Risk, Physician, Melanoma, Disease, Medical school, Mortality, Medical imaging, Dermatology, MD

Skin cancer is the most common form of cancer in the US, and melanoma is expected to be the second most common cancer in the US by 2040 [1].

Key Points: 
  • Skin cancer is the most common form of cancer in the US, and melanoma is expected to be the second most common cancer in the US by 2040 [1].
  • There are also over 200,000 PCPs in the United States who are well-positioned to detect and refer these skin cancers.
  • The device was granted FDA Breakthrough Device designation and is currently under review by the FDA.
  • Similarly, the DERM-SUCCESS Pivotal Study with 22 primary care study centers demonstrated 96% device sensitivity for all skin cancers in the primary care setting.

GT Medical Technologies Names Dr. Michael A. Garcia as Chief Medical Officer

Retrieved on: 
Thursday, March 16, 2023
Research, Radiation therapy, Health, Glioblastoma, Stanford University, Barrow Neurological Institute, MS, Patient, FDA, Brain, Associate, Biology, Harvard Medical School, DSM-IV codes, University, Walking, Nursing, Medical imaging, MD

TEMPE, Ariz., March 16, 2023 /PRNewswire/ -- GT Medical Technologies, Inc. has appointed Michael A. Garcia, MD, MS, as its Chief Medical Officer.

Key Points: 
  • TEMPE, Ariz., March 16, 2023 /PRNewswire/ -- GT Medical Technologies, Inc. has appointed Michael A. Garcia, MD, MS, as its Chief Medical Officer.
  • Dr. Garcia holds a bachelor's and master's degree in Biological Sciences from Stanford University and earned his medical degree from Harvard Medical School.
  • Prior to joining GT Medical Technologies, Dr. Garcia was an Associate Professor in Radiation Oncology at the Barrow Neurological Institute, a leading neurological disease treatment and research institution.
  • Dr. Garcia continued, "I'm so impressed with the work being done at GT Medical Technologies, especially for research and development, clinical trial design, and trial enrollment.

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma

Retrieved on: 
Thursday, March 16, 2023
Cancer, Chinese, PD, CR, DRS, Crownsville Hospital Center, CD8, KEAP1, Biomarker, Doctor of Pharmacy, CTC, ICB, Patient, Toxicity, Metastasis, NRF2, Melanoma, Massachusetts General Hospital, NPJ, Harvard Medical School, RNA, Doctor of Philosophy, DOI, Neoplasm, HIV disease progression rates, Vaccine, Medical imaging

BEVERLY, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces publication of data from the scientific founders that reveal downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade (ICB). The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3).

Key Points: 
  • The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3 ).
  • While ICB has significantly improved clinical outcomes in melanoma, a subset of patients do not respond or develop resistance over time.
  • “These exciting data demonstrate that isolation of CTCs from melanoma patients with the TellDx platform and subsequent single cell RNA sequencing can reveal pathways of response and resistance to ICB.
  • Overall, these data provide valuable insights into the mechanisms behind melanoma resistance to immune checkpoint blockade therapy and highlight the potential of monitoring CTCs to improve outcomes of patients with cancer.

ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

Retrieved on: 
Wednesday, March 15, 2023
Cancer, Hematological Cancer Research Investment and Education Act, Massachusetts General Hospital, MRD, Dor, Leukemia, Hospital, Phases of clinical research, FMS, Genomics, ISIN, Patient, Azacitidine, FDA, Associate, ASH, ALICE, ORY, ORR, FLT3, Harvard Medical School, Safety, LSD1, AML, Trial of the century, Recommender system, Pharmaceutical industry

FRIDA (NCT05546580) is an open-label, multicenter study of iadademstat plus gilteritinib for the treatment of patients with relapsed or refractory AML (R/R AML) with FLT3·mutations.

Key Points: 
  • FRIDA (NCT05546580) is an open-label, multicenter study of iadademstat plus gilteritinib for the treatment of patients with relapsed or refractory AML (R/R AML) with FLT3·mutations.
  • The trial’s principal investigator is Amir Fathi, M.D., Associate Professor at Harvard Medical School and Director of the Leukemia Program at Massachusetts General Hospital.
  • In a recently finalized Phase IIa study (ALICE trial) in elder/unfit AML patients, iadademstat demonstrated robust efficacy in combination with azacitidine, with 81% ORR in the evaluable patients, of which 64% were CR/CRi.
  • Final data from the ALICE trial were presented as an oral communication at the recent 64th ASH annual conference (see here for more details).

Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Research, Conference, Department of Neurology, Xuanwu hospital, Caregiver, University of Nevada, Las Vegas, Hospital, DSM-IV codes, International Conference on Emerging Infectious Diseases, Patient, UNLV, Banner Health, Symposium, Harvard Medical School, Therapy, AD, University, Pharmaceutical industry, Palladium, Brigham

In an oral presentation, Prothena will highlight new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease.

Key Points: 
  • In an oral presentation, Prothena will highlight new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease.
  • To build a more in-depth understanding of PRX012’s binding profile to Aβ protofibrils and its ability to clear pyroglutamate-Aβ from Alzheimer’s disease brain tissue, nonclinical studies compared a PRX012-surrogate* (PRX012s) to approved and investigational molecules.
  • Findings demonstrated that PRX012s had superior binding of 20-fold higher affinity to Aβ protofibrils as compared to lecanemab+ and mediated more robust phagocytic clearance of pyroglutamate-modified Aβ when compared to donanemab+.
  • These findings further support the ongoing clinical development of PRX012 as a potential best-in-class treatment for Alzheimer’s disease that could enable greater accessibility and more convenient administration for patients and caregivers.

Announcing Larry Chapman as the Keynote Speaker at the Wellness Workdays Emerging Trends in Workplace Wellness Conference

Retrieved on: 
Wednesday, March 15, 2023
Conference, Health, Learning, Workforce, City, Workweek and weekend, Pulse, SHRM, Certification, Christian democracy, Business case, Harvard Medical School, Mental health, Management, Nursing, New Balance

HINGHAM, Mass., March 15, 2023 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 10th Annual Emerging Trends in Wellness Conference on April 6, 2023. The virtual event will feature speakers who will highlight key strategies and initiatives employers can implement to develop a healthy and resilient workforce.

Key Points: 
  • Wellness Workdays' virtual conference will feature speakers from New Balance, Columbia Construction, Maine Bankers Association, City of Portland, Maine, and more!
  • HINGHAM, Mass., March 15, 2023 /PRNewswire-PRWeb/ -- Wellness Workdays, a leading provider of workplace wellness programs, will host its 10th Annual Emerging Trends in Wellness Conference on April 6, 2023.
  • Larry Chapman, President & CEO of The Chapman Institute, has been selected as the keynote speaker and will present Behind the Curtain; Examining the Business Case for Workplace Wellness.
  • Wellness Workdays is recognized by SHRM to offer Professional Development Credits (PDCs) for the SHRM-CPSM or SHRM-SCPSM.

ROTH MKM Announces the Addition of Dylan Dupuis, Ph.D. to its Healthcare Research Team

Retrieved on: 
Monday, March 13, 2023
Biotechnology, Finance, Banking, Health, Professional Services, History, Inflammation, Beth Israel Deaconess Medical Center, Harvard Medical School, SVB Securities, Lehigh University, CFA, DSM-IV codes, MKM, Doctor of Philosophy, Visium Asset Management, Molecular biology, Computational Biology and Chemistry, Lycoming College, Research fellow, Health care, Pharmaceutical industry, Altium, Chemistry, Biology, Research

ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Dylan Dupuis has joined the firm’s healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology.

Key Points: 
  • ROTH MKM (“Roth”), www.roth.com , a relationship-driven investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Dylan Dupuis has joined the firm’s healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology.
  • Prior to joining ROTH MKM, Dr. Dupuis was a SMID-cap Biotech Analyst at Altium Capital, a healthcare-focused hedge fund.
  • Prior to Altium, he spent two years at SVB Leerink as VP - Equity Research, Senior Associate.
  • Jeff Martin, CFA – Co-Director of Research, commented, “ROTH MKM continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform.